COVID-19 Resource Center

In the interest of supporting regulatory professionals addressing the unprecedented public health threat posed by COVID-19, AgencyIQ will be sharing all content concerning the virus and its regulatory implications on this page as the situation evolves in the coming weeks. 


AgencyIQ is a new division of POLITICO which provides regulatory analysis, data, and tools to regulatory affairs professionals in the pharmaceutical, biotechnology, and medical device industries. If you would like to learn more about AgencyIQ, please contact Alec Gaffney (agaffney@agencyiq.com) or Simmi Bhuller (sbhuller@politico.com).

AgencyIQ’s COVID-19 Tracker: The Vaccines & Therapies Being Tested

The pharmaceutical and biopharmaceutical industry is scrambling to put products into development to potentially treat, cure or prevent COVID-19 infections.

Based on a review by AgencyIQ of ClinicalTrials.gov, company announcements and media reports, there are at least 91 candidates in various stages of testing to assess their potential effects against COVID-19 or SARS-CoV-2, the virus which causes the condition. These products are already at various stages of development. Some have already been approved and are being assessed for their potential to treat COVID-19, while others are being repurposed from other late-stage development pipelines. Others are still in the very early stages of development and have not yet been tested in humans.

Read More »

Pandemics and intellectual property: How the government can impact COVID-19 drug and device development

The US patent landscape seeks to foster growth and innovation—especially in life sciences. But amid a global pandemic, public-private partnerships and government authority can impact an otherwise routine landscape of drug and device development. Here are four laws, regulations and international agreements that have implications for developers in the COVID-19 crisis.

Read More »